Search

Displaying results 8081 - 8090 of 10000 in total
  1. Drug

    VB2-011

    go.drugbank.com/drugs/DB05411
    Experimental

    VB2-011 is an antibody developed as an anti-cancer treatment. According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma. … This drug includes the parent IgM (H11 IgM) and a recombinant IgG version (H11 IgG).

  2. Drug

    Tifuvirtide

    go.drugbank.com/drugs/DB05413
    Investigational

    Tifuvirtide is the first members of a new class of anti-HIV drugs which is also called fusion inhibitors. It has received fast-track designation from the FDA and is in Phase I/II clinical testing.

  3. Drug

    CP-122721

    go.drugbank.com/drugs/DB05421
    Experimental

    CP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory diseases including asthma and irritable bowel syndrome.

    Categories: Heterocyclic Compounds, 1-Ring
  4. Drug

    Talactoferrin alfa

    go.drugbank.com/drugs/DB05426
    Investigational

    Talactoferrin alfa is a novel immunomodulatory 80 kD protein with demonstrated oral anti-tumor properties. Lactoferrin, a protein found in breast milk is developed by Agennix. … It increases body’s immune power and also works as a natural antioxidant, helping to control cell and tissue damage caused by oxidation.

  5. Drug

    IDD-3

    go.drugbank.com/drugs/DB05427
    Experimental

    IDD-3 is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. It consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. … It includes Dendritophages that are dendritic cells, a type of specialized immune cells derived from the patient's own white blood cells.

    Synonyms: IDD-3
  6. Drug

    VLTS-589

    go.drugbank.com/drugs/DB05430
    Investigational

    VLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.

  7. Drug

    MLN-977

    go.drugbank.com/drugs/DB05431
    Experimental

    MLN-977 is a small molecule compound that inhibits the production of leukotrienes, especially 5-lipoxygenase. It is developed by PharmaEngine to treat asthma and chronic obstructive pulmonary disease.

  8. Drug

    SRP 299

    go.drugbank.com/drugs/DB05440
    Experimental

    Mycobacterium vaccae is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity of regulatory T-cells that surpress inappropriate Th2 … A specific subset of serotonergic neurons in the interfascicular part of the dorsal raphe nucleus (DRI) is believed to be involved, based on studies with mice.

  9. Drug

    AVAC

    go.drugbank.com/drugs/DB05441
    Experimental

    AVAC is derived from M. vaccae. It has been tested in uses related to asthma and in treating eczema and atopic dermatitis. … [Mycobacterium vaccae] is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity of regulatory T-cells that surpress inappropriate

  10. Drug

    Iroxanadine

    go.drugbank.com/drugs/DB05444
    Experimental

    BRX-235 (iroxanadine) is a a novel small molecule synthesized by Biorex, Hungary that acts as a cardioprotective agent. … BRX-235 also causes translocation of calcium-dependent protein kinase C isoform to membranes.

    Categories: Heterocyclic Compounds, 1-Ring